Evogene

Company Overview

Snapshot

Founded in January 2002 by Rafi Meissner and Hagai Karchi, Evogene operates with 51–200 employees. The company has raised $135.7M across 10 funding rounds from 9 investors. In August 2024, Evogene announced the pricing of a $5.5 million registered direct offering.

Business overview

Evogene is a computational biology company focused on transforming product discovery and development across various life sciences industries, including human health and agriculture. The company's core technology is its Computational Predictive Biology (CPB) platform, which leverages big data and artificial intelligence to discover and guide the development of life science products based on microbes, small molecules, and genetic elements. Utilizing this platform, Evogene and its subsidiaries are advancing product pipelines for human microbiome-based therapeutics through Biomica Ltd, medical cannabis through Canonic Ltd, agricultural biologicals through Lavie Bio Ltd, agriculture chemicals through AgPlenus Ltd, and agriculture solutions for castor oil production through Castera Ltd.

Strategic signal

In October 2024, Evogene announced a collaboration with Google Cloud to develop a generative AI foundation model for novel small molecule design. This partnership signals Evogene's commitment to integrating advanced AI into its computational biology platform, potentially accelerating the discovery and development of new life science products and enhancing its competitive edge in the industry.

Company Intelligence Q&A

What was a significant recent collaboration for Evogene?

In October 2024, Evogene announced a collaboration with Google Cloud to pioneer a generative AI foundation model for novel small molecule design, aiming to accelerate discovery in life sciences.

What was a recent financial event for Evogene?

In August 2024, Evogene announced the pricing of a $5.5 million registered direct offering.

What is the status of Lavie Bio's bio-fungicide program?

In November 2024, Lavie Bio, an Evogene subsidiary, advanced its bio-fungicide LAV321, targeting Downy Mildew, to the pre-commercial stage following successful 2024 field trial results.

What is the latest development regarding Casterra's operations in Africa?

In October 2024, Casterra, an Evogene subsidiary, announced a key milestone in its operational expansion plan in Africa with the completion of the first shipment of castor seeds grown and processed in Kenya.

When did Evogene go public on NASDAQ?

Evogene went public on NASDAQ in November 2013.